Selected article for: "binding model and SARS bind"
Author: M. Gordon Joyce; Rajeshwer S. Sankhala; Wei-Hung Chen; Misook Choe; Hongjun Bai; Agnes Hajduczki; Lianying Yan; Spencer L. Sterling; Caroline E. Peterson; Ethan C. Green; Clayton Smith; Natalia de Val; Mihret Amare; Paul Scott; Eric D. Laing; Christopher C. Broder; Morgane Rolland; Nelson L. Michael; Kayvon Modjarrad
Title: A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
  • Document date: 2020_3_17
    • ID: ebbzx8yr_19
    Snippet: CR3022 to SARS-CoV-2 RBD measured by biolayer interferometry. Kinetic constants were determined were calculated using a minimum of four dilutions of the RBD and fitted using a 1:1 binding model. C,D, Competition binding of antibodies CR3022 and 240CD to SARS-CoV-2 RBD. CR3022 or control antibody was allowed to bind to SARS-COV-2 prior to binding to 240CD or vice-versa. E SARS-CoV-2 RBD was sequentially bound by antibodies CR3022 or 240CD followed.....
    Document: CR3022 to SARS-CoV-2 RBD measured by biolayer interferometry. Kinetic constants were determined were calculated using a minimum of four dilutions of the RBD and fitted using a 1:1 binding model. C,D, Competition binding of antibodies CR3022 and 240CD to SARS-CoV-2 RBD. CR3022 or control antibody was allowed to bind to SARS-COV-2 prior to binding to 240CD or vice-versa. E SARS-CoV-2 RBD was sequentially bound by antibodies CR3022 or 240CD followed by soluble human ACE2 receptor. F SARS-CoV reactive antibodies were assessed for binding to bat SARS-related CoV Rs4784 and Rs4231 S glycoproteins. Residues which differ between SARS-CoV-2 and SARS-CoV are colored red. The CR3022 epitope is outlined in blue, and Thr-430 and Phe-384 located within the epitope are labeled. C The location of antibody CR3022, 230S, 80R, m396 and F26G19 epitopes and ACE-2 binding site on the RBD are outlined on the surface of the SARS-CoV-2 RBD. a CC0 license.

    Search related documents:
    Co phrase search for related documents
    • bind site and RBD bind site: 1, 2
    • bind site and SARS bind: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • binding model and biolayer interferometry: 1
    • binding model and competition binding: 1
    • binding model and control antibody: 1, 2
    • binding model and SARS bind: 1, 2, 3, 4, 5
    • biolayer interferometry and CC0 license: 1, 2
    • biolayer interferometry and competition binding: 1, 2, 3
    • biolayer interferometry and control antibody: 1
    • biolayer interferometry and kinetic constant: 1
    • biolayer interferometry and SARS bind: 1
    • CC0 license and red color: 1
    • competition binding and control antibody: 1, 2
    • competition binding and SARS bind: 1, 2, 3, 4, 5, 6
    • control antibody and reactive antibody: 1
    • control antibody and red color: 1
    • control antibody and SARS bind: 1
    • reactive antibody and SARS bind: 1